Staar Surgical (NSDQ:STAA) announced today that it received CE Mark approval for its EVO Viva presbyiopia-correcting implantable Collamer lens (ICL).
Lake Forest, Calif.-based Staar Surgical is launching the EVO Viva through select doctors in Spain, Germany and Belgium, initially, with broader availability set to follow across Europe and other markets recognizing the CE Mark, according to a news release.
EVO Viva ICLs are implanted within the posterior chamber, directly behind the iris and in front of the anterior capsular bag to offer an intraocular alternative for the correction/reduction of refractive error in those who use spectacles and/or contact lenses for vision correction.
Staar’s next-generation ICL works with the patient’s eye to correct or reduce myopia and presbyopia in phakic and pseudo-phakic eyes, correcting their vision. Results from an investigation into the lens revealed that subjects reported significant improvements in quality of life and high levels of spectacle independence and satisfaction.
“The launch of EVO Viva significantly expands the market opportunity for our EVO family of lenses to now include lenses for patients suffering from presbyopia in the over 30 countries that currently recognize the CE Mark,” Staar Surgical president & CEO Caren Mason said in the news release. “EVO Viva reinforces our deep commitment to patients seeking visual freedom who have the express desire to get rid of their reading glasses. We believe EVO Viva can represent an attractive alternative among refractive surgery options currently available in the market today that require either ablating corneal tissue or removal of one’s healthy crystalline lens.”